Healthcare > Pharmaceuticals & Biotechnology
•2432 stocks
•
Total Market Cap: Loading...
Price Performance Heatmap
5Y Price (Market Cap Weighted)
All Stocks (2432)
| Company | Market Cap | Price |
|---|---|---|
|
PLUR
Pluri Inc.
Directly related to placenta-derived cell therapy products PLX-PAD/PLX-R18 and the company's 3D cell expansion platform used for cell therapies.
|
$33.04M |
$3.71
+3.92%
|
|
SCYX
SCYNEXIS, Inc.
SCYNEXIS's ibrexafungerp is a lead oral small-molecule therapeutic, fitting the 'Oral Small Molecule Therapeutics' category.
|
$32.49M |
$0.76
-1.43%
|
|
CELU
Celularity Inc.
Celularity's core products are allogeneic placental-derived cell therapies produced via the IMPACT platform.
|
$32.03M |
$1.15
-4.17%
|
|
RADX
Radiopharm Theranostics Limited
Core product category: Radiopharmaceuticals used for diagnostic imaging and therapy in oncology.
|
$31.82M |
$4.79
-0.73%
|
|
VNRX
VolitionRx Limited
Nu.Q Discover and Nu.Q Cancer positioning create companion diagnostic opportunities and biomarker-driven patient stratification.
|
$30.74M |
$0.36
+26.22%
|
|
PSTV
Plus Therapeutics, Inc.
Core product: radiopharmaceutical therapy using Rhenium-186 nanoliposomes for CNS cancers.
|
$30.63M |
$0.30
-2.37%
|
|
MDCX
Medicus Pharma Ltd. Common Stock
Directly markets/provides a proprietary drug-delivery platform (D-MNA) enabling localized chemotherapy delivery.
|
$30.17M |
$0.69
-49.78%
|
|
PDSB
PDS Biotechnology Corporation
Company is a oncology-focused biotech developing novel immunotherapies for HPV-related cancers (HPV16+ HNSCC).
|
$29.85M |
$0.66
+2.39%
|
|
DYAI
Dyadic International, Inc.
Company directly produces recombinant proteins and enzymes (e.g., RHSA, transferrin, DNase1, RNase inhibitors, FGF, lactalbumin, lactoferrin) for life sciences, diagnostics, and food/industrial uses.
|
$29.60M |
$0.81
-0.59%
|
|
ELUT
Elutia Inc.
EluPro embodies a Drug Delivery Platform delivering antibiotics from the biomatrix at the implant site.
|
$29.59M |
$0.70
-0.37%
|
|
BTAI
BioXcel Therapeutics, Inc.
BXCL501 is a small-molecule drug delivered as an oral dissolving film; fits 'Oral Small Molecule Therapeutics'.
|
$29.26M |
$2.04
-1.69%
|
|
EUDA
EUDA Health Holdings Limited
EUDA's core biotech activity is a stem cell platform and cell therapy development using iPSCs.
|
$29.25M |
$0.98
+24.46%
|
|
IKNA
Ikena Oncology, Inc.
ImageneBio's lead asset IMG-007 is a monoclonal antibody targeting OX40 for immunological/inflammatory diseases, aligning with Immunology Therapeutics.
|
$29.04M |
$7.22
|
|
ENLV
Enlivex Therapeutics Ltd.
Allocetra is Enlivex's lead cell therapy platform, directly produced and administered as a therapeutic cell product.
|
$28.63M |
$1.12
-6.25%
|
|
HOWL
Werewolf Therapeutics, Inc.
Werewolf Therapeutics develops conditionally activated immunotherapies for cancer, aligning with Biotech - Oncology.
|
$28.01M |
$0.59
-3.64%
|
|
LTRN
Lantern Pharma Inc.
Lantern is a biotech company with a focused oncology pipeline and programs.
|
$27.75M |
$2.52
-1.95%
|
|
PASG
Passage Bio, Inc.
PBFT02 is Passage Bio's lead gene therapy program directly developed by the company.
|
$26.83M |
$8.05
-4.62%
|
|
RNTX
Rein Therapeutics Inc.
IPF/related fibrotic orphan indications classify Rein's lead assets as addressing a rare disease space.
|
$26.57M |
$1.16
-3.33%
|
|
AYTU
Aytu BioPharma, Inc.
AYTU's core ADHD portfolio comprises oral small-molecule therapeutics (Adzenys XR-ODT, Cotempla XR-ODT) and Karbinal ER, fitting the 'Oral Small Molecule Therapeutics' category.
|
$26.54M |
$2.63
+0.96%
|
|
CCEL
Cryo-Cell International, Inc.
Cryo-Cell's core business is private cord blood and cord tissue stem cell collection, processing, and long-term cryogenic storage, aligning with the Biotech - Cell Therapy investable theme.
|
$26.38M |
$3.27
|
|
IGC
IGC Pharma, Inc.
Direct Alzheimer’s disease therapeutics pipeline with IGC-AD1 and disease-modifying candidates, the core product focus.
|
$26.32M |
$0.29
+0.76%
|
|
OTLK
Outlook Therapeutics, Inc.
ONS-5010/LYTENAVA is a regulatory-approved ophthalmic formulation of bevacizumab for intravitreal use.
|
$26.21M |
$0.60
+2.54%
|
|
CUE
Cue Biopharma, Inc.
CUE Biopharma is developing oncology-focused immunotherapies and cancer programs, aligning with Biotech - Oncology.
|
$25.93M |
$0.33
+9.43%
|
|
BOLD
Boundless Bio, Inc.
The company is a biotechnology firm focused on oncology, developing ecDNA-directed cancer therapies, which places it in Biotech - Oncology.
|
$25.52M |
$1.13
-0.88%
|
|
SNTI
Senti Biosciences, Inc.
Directly develops cancer therapies and immuno-oncology agents, notably SENTI-202 CAR-NK therapies targeting AML.
|
$24.91M |
$0.95
+0.14%
|
|
BRNS
Barinthus Biotherapeutics plc
Company is pivoting to immunology/inflammation therapeutics and is advancing T‑cell immunotherapies (SNAP-TI), with VTP-1000 for celiac disease as lead candidate.
|
$24.43M |
$0.61
+1.83%
|
|
MIRA
MIRA Pharmaceuticals, Inc.
Ketamir-2 is a novel oral small-molecule therapeutic targeting neuropathic pain, aligning with the 'Oral Small Molecule Therapeutics' category.
|
$24.22M |
$1.25
-1.97%
|
|
THAR
Tharimmune, Inc.
THAR directly develops monoclonal antibody therapeutics (e.g., TH023 and IO assets HS1940/HS3215), fitting Monoclonal Antibody Therapeutics.
|
$23.83M |
$4.74
-5.58%
|
|
ATHA
Athira Pharma, Inc.
ATH-1105 is described as an orally available, brain-penetrant small molecule developed for ALS, fitting the 'Oral Small Molecule Therapeutics' tag.
|
$23.58M |
$6.87
+22.24%
|
|
STCB
Starco Brands, Inc.
Vertical integration via acquisition of The Starco Group provides contract manufacturing capabilities.
|
$23.53M |
$0.03
|
|
VTGN
VistaGen Therapeutics, Inc.
Lead CNS pipeline focused on neuropsychiatric drug development (acute SAD, MDD) and related disorders.
|
$23.39M |
$0.56
-5.34%
|
|
JSPR
Jasper Therapeutics, Inc.
Core product briquilimab is a monoclonal antibody therapeutic, fitting Monoclonal Antibody Therapeutics.
|
$23.08M |
$1.35
-4.58%
|
|
DARE
Daré Bioscience, Inc.
Drug Delivery Platforms: Daré's core IDDS platform is used to deliver hormones and contraceptive agents (e.g., DARE-LARC1) and supports multiple pipeline programs, making this a primary product/technology category.
|
$22.92M |
$1.69
+0.90%
|
Showing page 20 of 25 (2432 total stocks)
Loading company comparison...
Loading industry trends...
Loading research report...
